Regeneron
$514.059876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$514.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$5.74 (+1.13%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours
Why Robinhood?
You can buy or sell Regeneron and other stocks, options, and ETFs commission-free!
About REGN
Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. The listed name for REGN is Regeneron Pharmaceuticals, Inc. Common Stock.
CEO
Leonard S. Schleifer
Employees
8,100
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
54.85B
Price-Earnings Ratio
18.79
Dividend Yield
—
Average Volume
964.31K
High Today
$518.92
Low Today
$509.20
Open Price
$513.69
Volume
497.79K
52 Week High
$664.64
52 Week Low
$328.13
Collections
REGN News
CNBCNov 23
CNBC Transcript: Regeneron Chairman and CEO Dr. Leonard Schleifer Speaks with CNBC's Meg Tirrell on "Squawk Box" Today
WHEN: TODAY, MONDAY, NOVEMBER 23
WHERE: CNBC'S "SQUAWK BOX"
Following is the unofficial transcript of a CNBC interview with Regeneron Chairman & CEO Dr. Leona
Analyst Ratings
52%
of 27 ratings
Buy
52%
Hold
44%
Sell
4%
REGN Earnings
$0.00
$2.79
$5.57
$8.36
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 4, Pre-Market
You May Also Like
More REGN News
CNBCNov 23
Regeneron CEO Dr. Leonard Schleifer on distribution of Covid-19 antibody cocktail
Regeneron CEO Dr. Leonard Schleifer on distribution of Covid-19 antibody cocktail
Regeneron CEO Dr. Leonard Schleifer said Monday morning that they'll have 300
CNBCNov 23
Stocks making the biggest moves in the premarket: Merck, Korn Ferry, Regeneron & more
Take a look at some of the biggest movers in the premarket:
Merck (MRK) – Merck is buying privately-held drug maker OncoImmune for $425 million cash. OncoImmun
Financial TimesNov 22
Coronavirus: Ohio has record one-day cases, Pennsylvania tightens restrictions — as it happened
Despite the pandemic, American consumers are forecast to open their wallets this holiday shopping season — even if they will be doing much of it online. Over th
New York TimesNov 22
Covid-19 Live Updates: Antibody Treatment Given to Trump Gets F.D.A. Emergency Approval
Live Updated Nov. 22, 2020, 10:55 a.m. ET Nov. 22, 2020, 10:55 a.m. ET Covid-19 Live Updates: Antibody Treatment Given to Trump Gets F.D.A. Emergency Approval N
